GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nautilus Biotechnology Inc (NAS:NAUT) » Definitions » Effective Interest Rate on Debt %

Nautilus Biotechnology (Nautilus Biotechnology) Effective Interest Rate on Debt % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nautilus Biotechnology Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Nautilus Biotechnology's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $0.00 Mil. Nautilus Biotechnology's average total debt for the quarter that ended in Mar. 2024 was $34.12 Mil. Therefore, Nautilus Biotechnology's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 0.00%.


Nautilus Biotechnology Effective Interest Rate on Debt % Historical Data

The historical data trend for Nautilus Biotechnology's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nautilus Biotechnology Effective Interest Rate on Debt % Chart

Nautilus Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
- - - -

Nautilus Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nautilus Biotechnology's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Nautilus Biotechnology's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nautilus Biotechnology's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nautilus Biotechnology's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Nautilus Biotechnology's Effective Interest Rate on Debt % falls into.



Nautilus Biotechnology Effective Interest Rate on Debt % Calculation

Nautilus Biotechnology's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  0/( (30.328+34.628)/ 2 )
=-1  *  0/32.478
=0.00 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=28.337 + 1.991
=30.328

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=31.09 + 3.538
=34.628

Nautilus Biotechnology's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Mar. 2024 ))/ count )
=-1  *  0/( (34.628+33.621)/ 2 )
=-1  *  0/34.1245
=0.00 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=31.09 + 3.538
=34.628

Total Debt  (Q: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=29.946 + 3.675
=33.621

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Nautilus Biotechnology  (NAS:NAUT) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Nautilus Biotechnology Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Nautilus Biotechnology's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nautilus Biotechnology (Nautilus Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
2701 Eastlake Avenue East, Seattle, WA, USA, 98102
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
Executives
Michael Seth Altman director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Subramanian Sankar officer: Senior VP, Product Development C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Gwen E Weld officer: Chief People Officer C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Anna Mowry officer: CFO and Treasurer C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Matthew B. Murphy officer: General Counsel C/O NAUTILUS BIOTECHNOLOGY, INC., 425 PONTIUS AVE N, STE 202, SEATTLE WA 98109
Sujal M Patel director, 10 percent owner, officer: CEO, President, and Secretary C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Mary E. Godwin officer: Senior VP, Operations 3101 WESTERN AVENUE, SEATTLE WA 98121
Karen Akinsanya director SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc director 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew S Mcilwain director 1000 SECOND AVENUE, SUITE 3700, SEATTLE WA 98104
Benjamin A Horowitz 10 percent owner 2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Marc L Andreessen 10 percent owner C/O ARNOLD & PORTER LLP, 3 EMBARCADERO CENTER 7TH FLOOR, SAN FRANCISCO CA 94111